FibroGen Collaborates with Regeneron Pharmaceuticals to Advance Immuno-Oncology Treatment for Solid Tumors

Published / Modified Jun 03 2024
CSIMarket Team / CSIMarket.com

SAN FRANCISCO, June 03, 2024 - FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company, has announced a clinical trial supply agreement with Regeneron Pharmaceuticals, a renowned pharmaceutical company specializing in innovative therapies. This collaboration aims to evaluate FibroGen's immuno-oncology assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in combination with Regeneron's cutting-edge anti-PD-1 therapy, LIBTAYO (cemiplimab), for the treatment of solid tumors.

The field of immuno-oncology has revolutionized cancer treatment, offering new hope and improved outcomes for patients worldwide. By harnessing the power of the immune system, these therapies have demonstrated remarkable efficacy against various types of cancers, including solid tumors. FibroGen's FG-3165 and FG-3175 hold great promise as novel immunotherapies, targeting specific pathways that contribute to tumor growth and evasion of the immune response.

This partnership seeks to leverage the synergistic potential of combining FibroGen's immuno-oncology assets with LIBTAYO, an established anti-PD-1 therapy. PD-1 inhibitors have shown significant success in enabling the immune system to recognize and attack cancer cells effectively. By utilizing FG-3165 and FG-3175 in combination with LIBTAYO, researchers aim to enhance the anti-tumor response and improve patient outcomes.

Solid tumors represent a significant therapeutic challenge due to their complex microenvironment, heterogeneity, and resistance mechanisms. The ability to overcome these hurdles and provide more effective treatments for solid tumors is crucial in advancing cancer care. This collaboration between FibroGen and Regeneron represents a significant step forward in meeting this challenge.

The clinical trial supply agreement will facilitate the initiation of upcoming clinical trials involving patients with solid tumors. It will assess the safety, tolerability, and efficacy of the combination therapy, comprising FG-3165 and FG-3175 alongside LIBTAYO. Innovative trial designs and rigorous scientific methodologies will guide the evaluation process, ensuring robust data collection and analysis.

The potential benefit of this collaborative effort extends beyond the two companies involved. Patients fighting solid tumors worldwide stand to gain from the accelerated development and commercialization of more effective immunotherapies. The combination therapy being evaluated has the potential to make a profound impact on patient outcomes and significantly improve overall survival rates.

FibroGen and Regeneron's commitment to bringing innovative treatments to patients is exemplified in this collaboration. By combining expertise, resources, and cutting-edge technologies, they aim to revolutionize immuno-oncology and transform the treatment landscape for those battling solid tumors.

In conclusion, FibroGen's clinical trial supply agreement with Regeneron Pharmaceuticals heralds a new era in the treatment of solid tumors. The combination of FG-3165 and FG-3175, alongside LIBTAYO, offers immense potential in enhancing the immune response against cancer cells. As researchers embark on these upcoming clinical trials, the prospect of improved outcomes and increased survival rates shines brightly for patients worldwide.


Sources for this article: Fibrogen Inc Press release, News Wire, Globe Newswire, Business wire, Pr newswire.... and CSIMarket.com Customer Analytics Research for Fibrogen Inc


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com